Product Description: Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.
Applications: COVID-19-immunoregulation
Formula: C51H70N10O12S2
Citations: Mol Med Rep. 2024 Jun;29(6):90./Nat Commun. 2023 Feb 21;14(1):962./Patent. US20240307504A1./Research Square Print. 2022 Aug./Basic Clin Pharmacol Toxicol. 2022 Jun 10./Biomacromolecules. 2024 Apr 23./Cell Mol Bioeng. 2022./Eur J Nucl Med Mol Imaging. 2024 Jul 18./Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec./J Pharm Biomed Anal. 11 December 2021, 114518./J Pharm Biomed Anal. 2022: 115156./J Pharm Sci. 2022 Oct 10;S0022-3549(22)00454-3./Mol Cancer. 2024 Sep 20;23(1):205.
References: [1]Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56./[2]Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.
CAS Number: 79517-01-4
Molecular Weight: 1079.29
Compound Purity: 99.97
Research Area: Inflammation/Immunology; Cardiovascular Disease; Endocrinology; Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 25 mg/mL (ultrasonic)
Target: Somatostatin Receptor
English
Deutsch
